Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven, localized (UICC stage I-II, T1-2, N1-2 or T3N0) or locally advanced (UICC stage III, T3-4, N+) gastric or Siewert Type II and III GE-junction adenocarcinoma. Tumor stage is determined by thoraco-abdominal CT-scan, EUS, as well as mandatory laparoscopy to rule out peritoneal carcinomatosis within 28 days prior to registration.~* ECOG-status 0-1~* Hematologic, liver, and renal function normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 12 months after completion of study treatment~Exclusion Criteria:~* Peritoneal carcinomatosis, as diagnosed by mandatory laparoscopy or distant metastasis~* Concurrent treatment with other experimental drugs or other anti-cancer therapy, or treatment within a clinical trial within 30 days prior to trial entry~* Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, no myocardial infarction within the last 12 months, unstable angina pectoris, or significant arrhythmia)~* Active or uncontrolled infection.~* Definitive contraindications for the use of corticosteroids as premedication~* Prior systemic (chemo- or targeted) treatment. Prior radiotherapy to the upper abdomen~* Any contraindication to treatment with cetuximab, capecitabine or cisplatin~* Any concomitant medication which is contraindicated for use with the trial drugs, such as sorivudin or brivudin~* HER-2 over expression, as determined by immunohistochemistry (IHC 3+) or the combination of IHC and FISH (IHC 2+/FISH+)~* Previous malignancy within 5 years, with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer~* Known hypersensitivity against any of the study drugs (cetuximab, cisplatin or capecitabine) or any component of the trial drugs~* Known deficit of dihydropyrimidine dehydrogenase~* Pre-existing peripheral neuropathy \> grade I~* Due to known interactions of coumarin antagonists (e.g. warfarin) and capecitabine patients requiring oral anticoagulation should be included in the study only after a switch from oral anticoagulation to low molecular weight heparin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cetuximab, capecitabine, cisplatin based chemoradiation (Type: EXPERIMENTAL): Induction chemotherapy:~3 cycles (of 3 weeks) with capecitabine, cisplatin and weekly cetuximab: Cetuximab 400mg/m2 (loading dose)on day 1 and 250mg/m2 weekly thereafter, Cisplatin 80mg/m2 on day 1 every three weeks, Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle.~Followed by:~Radio-chemo-immunotherapy:~Cetuximab 250mg/m2 weekly on day 1, Cisplatin 30mg/m2 weekly on day 1, Radiotherapy (dose escalation levels) 36/39.6/45 Gy(according to dose level) in 5 fractions of 1.8 Gy per week~Surgery:~Will be performed 4-6 weeks after neoadjuvant radiochemotherapy~Postoperative treatment:~3 cycles of Chemo-immunotherapy with cetuximab, cisplatin and capecitabine -as described above- will be administered postoperatively if the patient has recovered adequately from surgery and the treatment is considered as feasible by the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy